Thrombogenicity of beta 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster.
about
Dimers of beta 2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2'Pathophysiology of the antiphospholipid syndromeAttempts to make sense of the antiphospholipid syndrome.Inhibition of nitric oxide and antiphospholipid antibody-mediated thrombosis.β₂-Glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model.Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS.Role of tissue factor in a mouse model of thrombotic microangiopathy induced by antiphospholipid antibodiesPathophysiology of thrombosis and pregnancy morbidity in the antiphospholipid syndrome.A role for Toll-like receptor mediated signals in neutrophils in the pathogenesis of the anti-phospholipid syndrome.An A1-A1 mutant with improved binding and inhibition of β2GPI/antibody complexes in antiphospholipid syndrome.Current status and implications of autoimmune antiphospholipid antibodies in relation to thrombotic disease.Reduced beta 2 glycoprotein I improves diabetic nephropathy via inhibiting TGF-β1-p38 MAPK pathwayReduced beta 2 glycoprotein I improve diabetic nephropathy via inhibiting TGF-β1-p38 MAPK pathwayApolipoprotein E receptor 2 is involved in the thrombotic complications in a murine model of the antiphospholipid syndrome.The Effects of NF-κB and c-Jun/AP-1 on the Expression of Prothrombotic and Proinflammatory Molecules Induced by Anti-β2GPI in MouseCross-talk between the complement system and endothelial cells in physiologic conditions and in vascular diseases.Antiphospholipid antibodies: laboratory and pathogenetic aspects.Pathogenic role of antiphospholipid antibodiesSoluble analog of ApoER2 targeting beta2-glycoprotein I in immune complexes counteracts hypertension in lupus-prone mice with spontaneous antiphospholipid syndromePlatelets and the antiphospholipid syndrome.Inhibition of thrombotic properties of persistent autoimmune anti-β2GPI antibodies in the mouse model of antiphospholipid syndromeUse of monoclonal antibodies to dissect specificity and pathogenesis of antiphospholipid antibodies.Domain I of beta2-glycoprotein I: its role as an epitope and the potential to be developed as a specific target for the treatment of the antiphospholipid syndrome.Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment.β(2) -Glycoprotein I: evolution, structure and function.Pathogenesis of antiphospholipid syndrome: understanding the antibodies.Molecular pathophysiology of the antiphospholipid syndrome: the role of oxidative post-translational modification of beta 2 glycoprotein I.Pathophysiology of thrombotic APS: where do we stand?New Insights into the Molecular Basis of the Antiphospholipid Syndrome.Anti-β2-glycoprotein I antibodies.Dimerized Domain V of Beta2-Glycoprotein I Is Sufficient to Upregulate Procoagulant Activity in PMA-Treated U937 Monocytes and Require Intact Residues in Two Phospholipid-Binding Loops.Reduced beta 2 glycoprotein I prevents high glucose-induced cell death in HUVECs through miR-21/PTEN.Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo.Increased C1q, C4 and C3 deposition on platelets in patients with systemic lupus erythematosus--a possible link to venous thrombosis?In vivo effects of an inhibitor of nuclear factor-kappa B on thrombogenic properties of antiphospholipid antibodies.Antiphospholipid antibody-mediated effects in an arterial model of thrombosis are dependent on Toll-like receptor 4.Lupus anticoagulants and anticardiolipin antibodies: personal reminiscences, a little history, and some random thoughts.Cessation of oral anticoagulants in antiphospholipid syndrome.Novel therapies for the antiphospholipid syndrome.C5a receptor-deficient mice are protected from thrombophilia and endothelial cell activation induced by some antiphospholipid antibodies.
P2860
Q28179249-980F72FB-17F4-4689-8F89-6A70CBFC83ABQ28267421-2A2B44E5-C052-4A47-9DE7-23FA2CDA79CEQ33372890-BBDFE82A-3D45-4462-803D-DED3BB2956FDQ33406588-7BAA6D17-BFFD-419A-956A-5434508BDCC5Q33796355-B7B4E0D1-E272-49FE-AB69-ABA5F1085C9BQ33948737-0974AAE2-9617-4C7A-8235-6BBA08829123Q34080920-C28C8B35-90CF-4800-A5C7-88263D7BEE17Q34287356-906CD605-F2CF-4C03-BDE7-F0605D3E21B7Q34364580-ECF12C12-2916-48EA-A18F-59466C2D0DD9Q35152055-A9C5AF9F-6026-49D8-AA86-582D939706E3Q35181703-45247488-23B9-401D-86CC-8AD14E09A836Q35631986-4484FB2A-73E4-429F-BF5A-5E2D26C496F3Q35870605-DEE55826-92A0-4E2F-A4BB-F287379807CAQ35874202-553406CD-1AED-4A48-B97A-E0ECAC9757ECQ35909733-1A41C11E-690A-4E77-81F1-FB21CAB70841Q36573005-CD32058B-FBB4-4FA7-AAF6-C637B1CCA068Q36799474-84E80297-B526-45AD-BD45-52CE761B63AEQ37168017-E488BC40-1CF7-4382-ACBC-DF556E39EDA4Q37204282-26D1EF5A-CFAF-4C1E-A1C5-F79006279534Q37283013-893645AB-C0A5-4D90-B93B-79E1FE086FFCQ37585221-2B9109F8-1501-4125-B000-7037A551D6DAQ37721592-5F665AEC-581C-444A-BF04-85F62568B8C7Q37721607-0A629EB2-A9C6-441F-8FEF-D9C7AC4D8E56Q37842673-ED101E20-F329-4E1B-89E2-F868773989B3Q37871051-0698FF07-BB9C-450B-A6FB-32C49922E943Q37873720-CF3D8C3E-95DD-467D-BAF3-E7D6A98B72CEQ37903952-0127BCBC-A4B8-4A1F-866B-083EE311119CQ38013582-C47D78D3-578C-4780-B550-C798356625FFQ38024789-65C16680-AD0F-4C46-AF31-FA1FC603DB2FQ38108396-0843BFFE-FE1A-45AA-9E6B-0ADFF8F6C4AFQ41103646-3C8732AD-D278-4009-B234-8F1A328E51EDQ42106760-4FBDF816-CE78-4E7F-92B7-078EAA0D723EQ44106531-C7B6D6EE-F39A-4AEF-BF52-C641684ED956Q46275219-4A00A6D1-0F6B-4908-8CAB-E6F98E461314Q46982839-EE2CA496-993A-4DC8-A0B3-0E46FB75709CQ48074369-79BA2CEA-FE56-4A1D-9C99-3DDBC630B52BQ48629028-623A8DF5-74D0-4FD3-AE46-E53F5F858405Q50765317-73225C43-B739-4580-82D6-F41E7F4E89EDQ53495449-A1CFBD74-C4F4-4D5B-B196-AAC9134C208FQ53525527-876A492C-DFA7-4132-BD14-C5CD28025413
P2860
Thrombogenicity of beta 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Thrombogenicity of beta 2-glyc ...... rombosis model in the hamster.
@en
Thrombogenicity of beta 2-glyc ...... rombosis model in the hamster.
@nl
type
label
Thrombogenicity of beta 2-glyc ...... rombosis model in the hamster.
@en
Thrombogenicity of beta 2-glyc ...... rombosis model in the hamster.
@nl
prefLabel
Thrombogenicity of beta 2-glyc ...... rombosis model in the hamster.
@en
Thrombogenicity of beta 2-glyc ...... rombosis model in the hamster.
@nl
P2093
P1433
P1476
Thrombogenicity of beta 2-glyc ...... rombosis model in the hamster.
@en
P2093
Christine Wittevrongel
Doris Boon
Ingrid Vreys
Jef Arnout
Jos Vermylen
Marc F Hoylaerts
Milosz Jankowski
P304
P356
10.1182/BLOOD-2002-05-1310
P407
P577
2002-09-05T00:00:00Z